CA-NITRO-SOFTWARE
16.3.2023 01:05:39 CET | Business Wire | Press release
Nitro Software, a global leader in SaaS eSignature and PDF document solutions for businesses, announced today that Nitro Sign was again named a Leader in the GigaOm Radar Report for E-Signature Solutions.
Nitro Sign provides organizations with high-trust electronic signatures that meet or exceed global security and compliance standards, including multiple layers of protection and identity verification. The scalable solution also offers flexible integrations and APIs.
Identifying Nitro Sign as an industry Leader for the second year in a row, GigaOm acknowledged that the Nitro platform supports highly secure, end-to-end digital document processes with a seamless customer experience.
GigaOm’s 2023 Radar Report for E-Signature Solutions awarded Nitro Sign high scores for its:
- extensive compliance support, offering direct eID integration for over 30 jurisdictions
- leading data field configuration and analytics functionality
- best-in-class pricing tiers with minimal add-on fees
- automation and digitization across document workflows
- scalability and security due to its high-trust global data center strategy, extensive security provisions and tamper-proof seals at the signature (rather than envelope) level
GigaOm also noted that Nitro’s broad portfolio can support even the most complex use cases.
“The global adoption of eSignatures took off during the pandemic, and it only continues to accelerate,” said Nitro Chief Product Officer, Sam Thorpe. “Businesses of all sizes, around the world, benefit from the agility, efficiency and productivity eSignature technology enables. And while Nitro delivers a seamless customer experience, as the GigaOm Radar Report attests, there’s far more to our eSignature solutions than just enabling people to sign documents on their devices. Nitro has done the hard work behind the scenes to deliver an easy-to-use, high-trust solution that ensures our customers have the proper security, can avoid fraud and stay compliant.”
GigaOm’s Radar Report notes: “To be a significant player in this space, an e-signature solution must not only support the core e-signature process (preparation, distribution, execution) but also offer extensive compliance support, scalability for high-volume use cases, and flexibility across a range of countries, languages and interfaces. Functionality that simply allows a user to draw a signature on a document is not sufficient to be considered in this report.”
The report adds that “businesses are looking for end-to-end process capabilities rather than standalone solutions. In other words, e-signatures are viewed as a core component of broader document management suites, potentially not something an enterprise would purchase on its own. SMBs will shift more gradually to this strategy but will follow a similar path….”
In its 2023 Radar Report, GigaOm delivers comprehensive evaluations of 14 leading eSignature vendors, an analysis of each of their offerings and provides expert guidance on how to choose the right eSignature vendor for both small and medium business and enterprise requirements.
To read more about Nitro’s position and learn more about what’s happening with eSignatures, click here for a complimentary copy of the GigaOm Radar Report for E-Signature Solutions.
About Nitro Software
Nitro (ASX: NTO) is a global SaaS leader in PDF document management and eSigning. Nitro’s Productivity Platform includes powerful PDF tools, digital workflow automation, highly secure eSigning and identity capabilities. Its industry-leading analytics solution measures and quantifies ROI, usage and sustainability impact. With a best-in-class customer success team, Nitro supports more than 67% of the Fortune 500, 3 million licensed users and 13,000+ business customers across 157 countries. For more information: visit https://gonitro.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005670/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom